94 related articles for article (PubMed ID: 27701018)
1. DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas.
Ouyang Y; Zhong F; Wang Q; Ding L; Zhang P; Chen L; Wang Y; Cheng C
Leuk Res; 2016 Nov; 50():104-111. PubMed ID: 27701018
[TBL] [Abstract][Full Text] [Related]
2. ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas.
Zhu X; Miao X; Wu Y; Li C; Guo Y; Liu Y; Chen Y; Lu X; Wang Y; He S
Exp Cell Res; 2015 Jul; 335(2):216-23. PubMed ID: 26024773
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.
Yin H; Zhong F; Ouyang Y; Wang Q; Ding L; He S
Hematology; 2017 Oct; 22(9):527-535. PubMed ID: 28395594
[TBL] [Abstract][Full Text] [Related]
4. Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma.
Zhu X; Ouyang Y; Zhong F; Wang Q; Ding L; Zhang P; Chen L; Liu H; He S
Oncol Rep; 2017 Jan; 37(1):622-630. PubMed ID: 27840970
[TBL] [Abstract][Full Text] [Related]
5. Expression of small glutamine-rich TPR-containing protein A (SGTA) in Non-Hodgkin's Lymphomas promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR).
Wang Y; Huang Y; Xu X; Tang J; Huang X; Zhu J; Liu J; Miao X; Wu Y; Yang F; Ji L; He S
Leuk Res; 2014 Aug; 38(8):955-63. PubMed ID: 24974147
[TBL] [Abstract][Full Text] [Related]
6. Sam68 regulates cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) via the AKT pathway in non-Hodgkin's lymphoma.
Wu Y; Xu X; Miao X; Zhu X; Yin H; He Y; Li C; Liu Y; Chen Y; Lu X; Wang Y; He S
Cell Prolif; 2015 Dec; 48(6):682-90. PubMed ID: 26478515
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.
Miao X; Xu X; Wu Y; Zhu X; Chen X; Li C; Lu X; Chen Y; Liu Y; Huang J; Wang Y; He S
Tumour Biol; 2016 Jan; 37(1):1369-78. PubMed ID: 26298725
[TBL] [Abstract][Full Text] [Related]
8. Histamine-releasing factor/translationally controlled tumor protein plays a role in induced cell adhesion, apoptosis resistance and chemoresistance in non-Hodgkin lymphomas.
He S; Huang Y; Wang Y; Tang J; Song Y; Yu X; Ma J; Wang S; Yin H; Li Q; Ji L; Xu X
Leuk Lymphoma; 2015 Jul; 56(7):2153-61. PubMed ID: 25363345
[TBL] [Abstract][Full Text] [Related]
9. DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation.
Wang L; Cao XX; Chen Q; Zhu TF; Zhu HG; Zheng L
Cancer Sci; 2009 Oct; 100(10):1801-8. PubMed ID: 19572978
[TBL] [Abstract][Full Text] [Related]
10. DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT/AP-1 pathway.
Xu Z; Liu D; Fan C; Luan L; Zhang X; Wang E
Mol Carcinog; 2014 Nov; 53(11):917-25. PubMed ID: 23813858
[TBL] [Abstract][Full Text] [Related]
11. Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Wang Y; Wu Y; Miao X; Zhu X; Miao X; He Y; Zhong F; Ding L; Liu J; Tang J; Huang Y; Xu X; He S
Int J Biol Macromol; 2015 Nov; 81():809-17. PubMed ID: 26341817
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Zhu X; Chen X; Li C; Zong G; Zhou G; Wan C
Hum Pathol; 2016 Nov; 57():182-192. PubMed ID: 27498060
[TBL] [Abstract][Full Text] [Related]
13. DIXDC1 promotes the growth of acute myeloid leukemia cells by upregulating the Wnt/β-catenin signaling pathway.
Xin H; Li C; Wang M
Biomed Pharmacother; 2018 Nov; 107():1548-1555. PubMed ID: 30257373
[TBL] [Abstract][Full Text] [Related]
14. [MicroRNA-138 regulates cell adhesion-mediated drug resistance phenotype by targeting SGTA in non-Hodgkin's lymphoma].
Wu YX; He S; Xu XH
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):668-673. PubMed ID: 30180469
[No Abstract] [Full Text] [Related]
15. Dixdc1 targets CyclinD1 and p21 via PI3K pathway activation to promote Schwann cell proliferation after sciatic nerve crush.
Wu W; Liu Q; Liu Y; Yu Z; Wang Y
Biochem Biophys Res Commun; 2016 Sep; 478(2):956-63. PubMed ID: 27521891
[TBL] [Abstract][Full Text] [Related]
16. A novel monoclonal antibody specific to DIXDC1 protein.
Liu T; Wang L; Chen Q; Zheng L; Zhu H
Hybridoma (Larchmt); 2009 Jun; 28(3):183-8. PubMed ID: 19519246
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of DIXDC1 Inhibits the Proliferation and Migration of Human Glioma Cells.
Chen J; Shen C; Shi J; Shen J; Chen W; Sun J; Fan S; Bei Y; Xu P; Chang H; Jiang R; Hua L; Ji B; Huang Q
Cell Mol Neurobiol; 2017 Aug; 37(6):1009-1019. PubMed ID: 27817168
[TBL] [Abstract][Full Text] [Related]
18. Statins as the Controlling Agents for Non-Hodgkin's Lymphomas via Increasing the Casein Kinase 2 Interacting Protein-1: A Hypothesis.
Kazemi K; Mozafari N; Ashrafi H; Rafiei P; Azadi A
Curr Drug Discov Technol; 2020; 17(5):616-618. PubMed ID: 31264550
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Disheveled-Axin Domain Containing 1 (DIXDC1) by MicroRNA-186 Inhibits the Proliferation and Invasion of Retinoblastoma Cells.
Che X; Qian Y; Li D
J Mol Neurosci; 2018 Feb; 64(2):252-261. PubMed ID: 29264763
[TBL] [Abstract][Full Text] [Related]
20. DIXDC1 promotes retinoic acid-induced neuronal differentiation and inhibits gliogenesis in P19 cells.
Jing XT; Wu HT; Wu Y; Ma X; Liu SH; Wu YR; Ding XF; Peng XZ; Qiang BQ; Yuan JG; Fan WH; Fan M
Cell Mol Neurobiol; 2009 Feb; 29(1):55-67. PubMed ID: 18629627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
